← Leaderboards
Brent Keith Blackburn
Amygdala Neurosciences, Inc.
$2,279,500
Attributed
$2,279,500
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.1M · FY2021–24$2M$1.5M$1M$500K$0
'21
'22
'23
'24
Funding mix
By agency
NIH$2,279,500 · 2
By mechanism
U43$2,055,000 · 1
R43$224,500 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Lynn Briscoe · Leidos Biomedical Research, Inc.$97,151,761
- Beth Baseler · Leidos Biomedical Research, Inc.$87,027,148
Research focus
Pharmaceutical PreparationsDisulfiramSocietiesAdultGrantAlcohol ConsumptionOralPre-ClinicalClinical DataEconomic CostAmericanAlcohol Use DisorderAlcohol Abuse TherapyEnzymesCravingDiagnosisFda ApprovedDrinkingAnxietyCognitive TherapyAttributable MortalityAmygdaloid StructureAlcoholsAcamprosate
Grant awards (4)
Investigational New Drug (IND)-enabling and Early-Stage Development of Selective, Reversible, Orally Bioavailable ALDH2 inhibitor ANS-00858 to Treat Alcohol Use Disorder.$1,000,000
U43 · FY2024 · AA · contact PI
Investigational New Drug (IND)-enabling and Early-Stage Development of Selective, Reversible, Orally Bioavailable ALDH2 inhibitor ANS-00858 to Treat Alcohol Use Disorder.$55,000
U43 · FY2024 · AA · contact PI
Investigational New Drug (IND)-enabling and Early-Stage Development of Selective, Reversible, Orally Bioavailable ALDH2 inhibitor ANS-00858 to Treat Alcohol Use Disorder.$1,000,000
U43 · FY2023 · AA · contact PI
Discovery next generation inhibitors of ALDH2 to reduce craving and alcohol consumption in alcohol use disorders$224,500
R43 · FY2021 · AA · contact PI